Microba Life Sciences Limited (MAP) AI Stock Analysis

• Market Cap: AU$54.20M
• Dividend Yield: N/A
• Average Volume (3M): 469.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: 29.60%
• EPS Growth: 33.00%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.02
• Shares Outstanding: 608,963,000
• 10 Day Avg. Volume: 548,444
• 30 Day Avg. Volume: 469,774
• PEG Ratio: 0.08
• Price to Book (P/B): 1.17
• Price to Sales (P/S): 2.43
• P/FCF Ratio: -2.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.21
• Price Target Upside: 162.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: AU$0.10 ▲(23.75% Upside)

The score is primarily constrained by weak financial performance, including falling revenue and persistent losses with negative operating cash flow. Technical indicators are comparatively supportive (price above key moving averages and positive MACD), but valuation is difficult to assess given the negative P/E and no dividend data.

Positive Factors

Diversified revenue streams

Microba sells consumer/clinician tests, B2B sequencing/bioinformatics services and collaboration work. This multi-channel model spreads commercial risk, supports recurring and project revenue, and leverages its platform and datasets for durable demand across customers and research partners.

Low financial leverage

A low debt-to-equity ratio provides financial flexibility and lower fixed interest costs, allowing the company to invest in R&D, lab capacity or partnerships without immediate refinancing pressure. This strengthens resilience to revenue volatility over the coming months.

Positive free cash flow growth

Reported FCF growth and FCF exceeding net income indicate the business can generate cash even while accounting losses persist. That cash generation can extend runway, fund critical operations or targeted investments, and reduce near-term reliance on external capital.

Negative Factors

Declining revenue

A 24% decline in revenue is a structural concern: it reduces operating leverage, constrains margins, and limits reinvestment into product development and commercialisation. If sustained over 2–6 months it undermines growth prospects and increases funding needs.

Persistent operating losses

Negative profitability across net, EBIT and EBITDA margins signals that core operations do not cover costs. Persistent losses erode equity, suppress ROE, and limit the ability to self-fund expansion or absorb setbacks, creating structural pressure on strategic options.

Negative operating cash flow

Negative operating cash flow means core activities are not generating cash to sustain operations. Over months this increases dependence on financing or equity raises, constrains discretionary spending on R&D and commercialisation, and raises execution risk.

Microba Life Sciences Limited Business Overview & Revenue Model

Company Description

Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.

How the Company Makes Money

Microba Life Sciences generates revenue through multiple channels, primarily by offering microbiome testing services to both consumers and healthcare providers. Revenue is derived from direct-to-consumer sales of its microbiome testing kits, which analyze gut health and provide personalized reports based on the findings. Additionally, the company likely collaborates with research institutions and pharmaceutical companies, providing microbiome data and insights that can aid in drug development and personalized medicine. Partnerships with healthcare organizations may also contribute to its revenue by integrating microbiome analysis into clinical practices. This diversified revenue model allows Microba to leverage its expertise in the microbiome field while expanding its market reach.

Microba Life Sciences Limited Financial Statement Overview

Summary

Weak fundamentals: revenue is declining (-24.28%) and profitability is negative (net profit, EBIT, and EBITDA margins all below zero). Balance sheet leverage is low (debt-to-equity 0.10), but negative ROE and negative operating cash flow indicate ongoing operating strain despite slightly positive free cash flow growth.

Income Statement

Microba Life Sciences Limited has experienced declining revenue growth, with a negative growth rate of -24.28% in the latest period. The company is operating at a loss, as indicated by negative net profit, EBIT, and EBITDA margins. Despite a relatively stable gross profit margin, the overall profitability is weak due to high operating expenses.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio of 0.10, indicating low leverage and financial risk. However, the return on equity is negative, reflecting ongoing losses. The equity ratio suggests a strong equity base relative to total assets, but profitability remains a concern.

Cash Flow

Microba Life Sciences Limited has a positive free cash flow growth rate of 4.68%, but operating cash flow remains negative. The free cash flow to net income ratio is above 1, indicating that free cash flow exceeds net income, which is a positive sign. However, the negative operating cash flow coverage ratio highlights cash flow challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	15.67M	15.67M	12.09M	5.42M	4.69M	3.73M
Gross Profit	7.44M	7.44M	5.91M	-6.77M	2.37M	-5.30M
EBITDA	-22.47M	-10.51M	-17.10M	-17.07M	-9.86M	-6.28M
Net Income	-14.94M	-14.94M	-19.94M	-12.68M	-11.47M	-7.52M
Balance Sheet
Total Assets	47.44M	47.44M	58.04M	46.95M	39.48M	18.49M
Cash, Cash Equivalents and Short-Term Investments	11.74M	11.74M	20.89M	32.04M	30.79M	13.03M
Total Debt	3.23M	3.23M	1.58M	1.14M	1.33M	269.02K
Total Liabilities	14.94M	14.94M	16.82M	8.23M	5.94M	3.55M
Stockholders Equity	32.49M	32.49M	41.22M	38.57M	33.54M	14.94M
Cash Flow
Free Cash Flow	-12.34M	-14.91M	-19.95M	-15.43M	-12.32M	-7.85M
Operating Cash Flow	-12.01M	-12.01M	-15.57M	-12.39M	-10.45M	-7.18M
Investing Cash Flow	-2.83M	-2.83M	-13.95M	-3.00M	-1.73M	-522.48K
Financing Cash Flow	5.58M	5.58M	18.39M	16.68M	29.22M	13.84M

Microba Life Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MAP, the sentiment is Positive. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.91 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MAP.

Microba Life Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	64 Neutral	AU$51.74M	27.46	98.18%	―	11.93%	2.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAP	49 Neutral	AU$54.20M	-2.67	-40.54%	―	29.60%	33.00%
BDX	45 Neutral	AU$44.17M	-6.06	-97.79%	―	―	23.85%
LDX	42 Neutral	AU$170.38M	-13.35	-111.23%	―	12.96%	40.81%
GSS	40 Underperform	AU$35.21M	-1.71	-36.16%	―	62.81%	16.37%
IIQ	38 Underperform	AU$49.98M	-5.70	-37.78%	―	2.33%	12.50%

Microba Life Sciences Limited Corporate Events

Microba to Release Q2 FY26 Report and Host Investor Webinar

Microba Life Sciences Limited has announced it will release its Q2 FY26 Quarterly Activities Report, cash flow statement and investor presentation on 29 January 2026, alongside hosting a quarterly investor webinar presented by CEO Dr Luke Reid. The company is directing investors to its interactive Investor Hub for webinar registration, advance question submission and ongoing access to announcements, reflecting a push to deepen engagement with shareholders and improve transparency around its operational and financial performance.

The most recent analyst rating on (AU:MAP) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Boosted by $3 Million R&D Tax Incentive Refund

Microba Life Sciences Limited has received a $3 million R&D Tax Incentive refund from the Australian Government for its research and development activities in the 2024/2025 financial year. This financial boost strengthens Microba’s cash position and supports its ongoing innovation in gastrointestinal diagnostics and therapeutics, which are pivotal in delivering transformative health outcomes globally.

The most recent analyst rating on (AU:MAP) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Announces Director Change

Microba Life Sciences Limited announced the cessation of Dr. Hyungtae Kim as a director, effective November 19, 2025. Dr. Kim, who was a director nominee of Macrogen, Inc., held 17,828,431 ordinary fully paid shares in the company. This change in directorship may influence the company’s strategic direction and stakeholder relationships, particularly with Macrogen, Inc.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Passes Key Resolutions at AGM

Microba Life Sciences Limited held its Annual General Meeting, where all proposed resolutions were passed, except for the re-election of Dr. Hyungtae Kim, who retired. Notably, the approval of a 10% Placement Facility was achieved, which could enhance the company’s financial flexibility and strategic positioning.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Announces Board Renewal to Boost Global Growth

Microba Life Sciences Limited has announced a board renewal process, appointing Mr. Stéphane Chatonsky as an Independent Non-Executive Director to enhance its global commercialization strategy and accelerate the growth of its microbiome testing business. This appointment, effective November 20, 2025, follows the retirement of Non-Executive Directors Mr. Richard Bund and Dr. Hyungtae Kim, who have significantly contributed to the company’s governance and strategic evolution. The board changes aim to strengthen Microba’s position in the industry as it continues to expand its operations globally.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Enhances Investor Engagement with Q1 FY26 Webinar

Microba Life Sciences Limited announced its Q1 FY26 Investor Presentation and Webinar, which will be led by CEO Dr. Luke Reid. The company invites investors to engage through its interactive investor platform, where they can register for the webinar, submit questions, and receive updates on the company’s quarterly reports and key announcements. This initiative aims to enhance investor engagement and transparency, potentially strengthening Microba’s market position and stakeholder relations.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Achieves Strong Growth in Core Testing Products

Microba Life Sciences Limited reported significant growth in its core testing products for Q1 FY26, with a 145% increase in test volumes compared to the previous corresponding period. The company is on track to meet its regional break-even guidance by the end of FY26, driven by strong sales growth in Australia and the UK. The strategic shift to focus on high-margin growth products has resulted in a 42% revenue increase, excluding legacy products, and a 26% reduction in operating expenditure. Microba’s transition to core growth products is expected to enhance profitability and operational efficiency, supported by a recent capital raise and ongoing cost management initiatives.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.